Research
Hormonal
Activation of the GIP receptor, but not the GLP-1 receptor, increases plasma resistin levels.
This finding suggests that GIP receptor activation specifically influences resistin levels, a marker associated with insulin resistance. This adds nuance to the understanding of how different incretin pathways affect metabolic health markers beyond glucose and weight.
GoodSupportsHIGH confidence
the GIP receptor agonist [D-Ala2]GIP, but not the GLP-1 receptor agonist exendin-4, increased the levels of plasma resistin in studies of both acute and chronic administration.
Why this rating
Clear experimental evidence in mice, but the clinical significance of resistin elevation is not fully established.
Source
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
Tanya Hansotia et al. · Journal of Clinical Investigation · 2006
DOI 10.1172/jci25483
mechanism_onlyCited 286×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →